- Investing Ideas
- /
- Australian Pharmaceuticals & Biotech High Growth Potential Companies
Australian Pharmaceuticals & Biotech High Growth Potential Companies
Results
14
Companies with a Future performance score of at least 3, ordered by Future performance score.
14 companies
Acrux
Market Cap: AU$9.8m
Engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally.
ACR
AU$0.024
7D
9.1%
1Y
-61.9%
Botanix Pharmaceuticals
Market Cap: AU$650.6m
Engages in the research and development of dermatology and antimicrobial products in Australia and the United States.
BOT
AU$0.35
7D
-11.3%
1Y
73.2%
Telix Pharmaceuticals
Market Cap: AU$8.8b
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States.
TLX
AU$26.19
7D
10.8%
1Y
102.6%
Little Green Pharma
Market Cap: AU$36.3m
Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.
LGP
AU$0.12
7D
0%
1Y
-14.3%
Clinuvel Pharmaceuticals
Market Cap: AU$529.4m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$10.60
7D
0.6%
1Y
-29.8%
Aroa Biosurgery
Market Cap: AU$134.5m
Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
ARX
AU$0.39
7D
-6.0%
1Y
-31.0%
Clarity Pharmaceuticals
Market Cap: AU$519.0m
A clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States.
CU6
AU$1.62
7D
-3.9%
1Y
-40.2%
Genetic Signatures
Market Cap: AU$85.2m
Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.
GSS
AU$0.38
7D
-24.2%
1Y
-45.7%
PYC Therapeutics
Market Cap: AU$539.9m
A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.
PYC
AU$0.98
7D
-10.1%
1Y
2.1%
Medical Developments International
Market Cap: AU$56.3m
Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.
MVP
AU$0.50
7D
-3.8%
1Y
-14.5%
Mayne Pharma Group
Market Cap: AU$567.1m
A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.
MYX
AU$6.98
7D
-3.2%
1Y
-1.1%
EZZ Life Science Holdings
Market Cap: AU$68.9m
Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and internationally.
EZZ
AU$1.46
7D
0%
1Y
73.8%
Trajan Group Holdings
Market Cap: AU$131.0m
Develops, manufactures, sells, and distributes analytical and life science products and devices in Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India.
TRJ
AU$0.86
7D
11.0%
1Y
-32.5%
CSL
Market Cap: AU$112.9b
Researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
CSL
AU$233.08
7D
-8.0%
1Y
-17.3%